BC-2細(xì)胞

組織來源： pleural effusion

生長(zhǎng)狀態(tài)： 懸浮生長(zhǎng)

年限： 31 years *****

細(xì)胞類型： B**細(xì)胞

是否是腫瘤細(xì)胞： 1

物種來源： 人

ATCC Number： CRL-2231?

相關(guān)**： **瘤

數(shù)量： 大量

運(yùn)輸方式： 凍存運(yùn)輸

細(xì)胞形態(tài)： **樣

BC-2細(xì)胞Designations: BC-2

Depositors: Cornell Res. Fndn., Inc.

Biosafety Level: 2 [Cells contain EBV and KSHV (HHV-8) viral genomes ]

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: suspension

Organism: Homo sapiens

Morphology: lymphoblast

Source: Tissue: pleural effusion

Disease: lymphoma

Cell Type: B lymphocyte;

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. BC-2細(xì)胞Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Applications: transfection host (Roche Transfection Reagents)

Antigen Expression: CD45 +; EMA + (epithelial membrane antigen)

Age: 31 years *****

Gender: male

Ethnicity: Caucasian

Comments: BC-2 is a lymphoma cell line originated in 1992 by Ethel Cesarman and Giorgio Inghirami in the laboratory of Daniel M. Knowles.

The cells were derived from a pleural cavity based lymphomatous effusion.

The cells contain two viral genomes: Epstein-Barr virus (EBV) and Kaposi sarcoma associated herpesvirus (KSHV, provisionally designed HHV-8).

KSHV is a recently identified and largely uncharacterized virus.

BC-2細(xì)胞The BC-2 cell line allows in vitro culture of KSHV viral genomes.

It is also a practical source of KSHV DNA to be used as a positive control for screening tests.

Propagation: ATCC complete growth medium: RPMI 1640 medium, 80%; fetal bovine serum, 20%

Subculturing: Medium Renewal: Every 2 to 3 days

Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 5 X 10 exp5 cells/ml and maintain between 5 X 10 exp5 and 2 X 10 exp6 cells/ml.

Preservation: Culture medium, 95%; DMSO, 5%

Doubling Time: 48 to 72 hrs

References: 22572: Moore PS, et al. Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma. J. Virol. 70: 549-558, 1996. PubMed: 8523568

23358: Cesarman E, et al. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 86: 2708-2714, 1995. PubMed: 7670109

23395: Chadburn A, et al. CD30 (Ki-1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus. Cancer 72: 3078-3090, 1993. BC-2細(xì)胞PubMed: 8221575

23493: Cesarman E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS- related body-cavity-based lymphomas. N. Engl. J. Med. 332: 1186-1191, 1995. PubMed: 7700311

39036: Cesarman E, et al. KSHV positive cell lines. US Patent 5,908,773 dated Jun 1 1999